New Generation Cardiac Troponin I Assay for the Access Immunoassay System

Publisher Website
Google Scholar
Abstract
The measurement of troponins in blood has rapidly become an alternative to conventional methods of detecting myocardial damage (1)(2)(3)(4)(5)(6)(7)(8), particularly in unstable angina, and several studies have indicated the prognostic importance of increased troponins in various clinical settings (9)(10)(11)(12)(13)(14). These studies, however, have also pointed out the need for more sensitive methods because patients with even small increases of troponin seem to be at increased risk of cardiac events. Currently, cardiac troponin I (cTnI) can be quantified by assays from several manufacturers (15)(16)(17)(18)(19), whereas only one company currently commercializes a cardiac troponin T assay (2)(20)(21). The aim of this work was to evaluate the analytical performance of a new generation of the Access cTnI assay. We also provide data on values in apparently healthy subjects.